B
HZNP

Bailard’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bailard’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-47,513
Closed -$5.5M – 840
2023
Q3 		$5.5M Sell
47,513
-1,612
-3% -$173K 0.18% 113
2023
Q2 		$5.05M Sell
49,125
-58
-0.1% -$6.12K 0.18% 113
2023
Q1 		$5.37M Sell
49,183
-58,395
-54% -$6.45M 0.19% 108
2022
Q4 		$12.2M Sell
107,578
-13,739
-11% -$1.14M 0.47% 47
2022
Q3 		$7.51M Sell
121,317
-33,884
-22% -$2.37M 0.31% 76
2022
Q2 		$12.4M Buy
155,201
+5,727
+4% +$542K 0.49% 43
2022
Q1 		$15.7M Sell
149,474
-76
-0.1% -$7.41K 0.53% 43
2021
Q4 		$16.1M Sell
149,550
-53
-0% -$5.78K 0.51% 44
2021
Q3 		$16.4M Buy
149,603
+3,106
+2% +$322K 0.56% 40
2021
Q2 		$13.7M Buy
146,497
+10,800
+8% +$994K 0.47% 48
2021
Q1 		$12.5M Buy
+135,697
New +$11.5M 0.46% 46

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bailard's HZNP Position: Q4 2023 in Review

Bailard sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 47,513 shares — an estimated $5.5M sold.

Bailard first reported a position in HZNP in Q1 2021 and held it in 11 quarters. The position peaked at $16.4M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bailard reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bailard sold 47,513 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.5M.
  • Bailard first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 11 quarters.
  • Bailard's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16.4M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bailard's 13F filing for Q4 2023, filed 2 Feb 2024.